The Application of Monoclonal Antibodies for the Definition of Genetic Markers of Human Red Cells

Voak, D.; Davies, D. A. L.; Sonneborn, H.‐H.; Moulds, John J.; Fletcher, Anne; Downie, D. M.

doi:10.1007/978-3-642-73330-7_56

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of A1 (B)-enhanced tests, especially protease enzymes, demonstrated the presence of a little B on all adult AI red cells just as protease enzyme B (A) tests have demonstrated a little A on all adult B cells (Beck et al, 1987;Stroup & Treacy, 1987;Voak et al, 1988;Goldstein et al, 1989). We could not however, demonstrate A1 (B) reactions with A2 RBC and it would appear that A2 transferase enzymes do not have the capacity to transfer galactose to available H sites on A2 RBC, or alternatively do not produce sufficient B antigen to be detectable.…”

Section: Discussionmentioning

confidence: 99%

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells

Voak

Sonneborn

Yates

1992

Transfusion Medicine

Self Cite

View full text Add to dashboard Cite

A monoclonal anti-B (BS 85) that reacts strongly with red cells from weak B variants (B3, Bint and Bv) has demonstrated the presence of a trace of B on A1 red cells. The agglutination of group A1 red cells by an anti-B antibody is called the A1 (B) phenomenon and is the converse of the B(A) phenomenon seen with certain monoclonal anti-A antibodies. Fragile A1 (B) agglutination is best seen by spin-tube techniques and A1 red cells negative in saline tests are agglutinated by albumin and protease enzyme-enhanced tests, but no reactions are seen with A2 red cells. The A1 (B) reaction is specifically inhibited by B substance, and D-galactose and the galactose-containing sugars melibiose and lactose. Red cells from B variants showed differential inhibition patterns with various sugars. A1 transferase levels were normal even in the strongest A1 (B) reactive blood samples, although the plasma H transferase levels and H status of these red cells were elevated. This is in contrast to the B(A) phenomenon which is associated with elevated levels of B transferase. It is suggested that A1(B) overlapping specificity can occur because of a combination of higher H activity (and thus more H sites) together with normal levels of A transferase activity as they are 20% higher than normal levels of B transferase. The production of anti-B reagents free of the A1 (B) phenomenon with BS-85 is achieved by suitable dilution using quality control tests with protease-treated A1 red cells.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Discussionmentioning

confidence: 99%

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells

Voak

Sonneborn

Yates

1992

Transfusion Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Monoclonal antibodies in blood group serology

Voak¹

1989

Transfusion Science

View full text Add to dashboard Cite

Enzyme and DTT treatment of adherent RBCs for antibody identification by a solid phase immunoassay system

Tamai

Mazda

2002

Immunohematology

View full text Add to dashboard Cite

Treatment of RBCs with protease enzymes or dithiothreitol (DTT) causes denaturation of several RBC antigens and is regularly used in antibody identification. In this study, we have standardized enzyme and DTT treatment of adherent RBCs in the magnetic-mixed passive hemagglutination assay (M-MPHA) for antibody identification. We have also tried drying these treated RBCs. The optimal enzyme and DTT treatment conditions for intact adherent RBCs were determined, in addition to the optimal condition for drying RBCs. All tested agents with the exception of chymotrypsin could be applied to RBC drying, but the optimal condition for drying was different from that for intact RBCs. Enzyme or DTT treatment of adherent RBCs and their application in M-MPHA provide a simple and convenient method for antibody identification. Furthermore, the technique of drying treated RBCs provides an even stronger antibody identification tool, since dried RBCs can be stored for a long period.

show abstract

The Application of Monoclonal Antibodies for the Definition of Genetic Markers of Human Red Cells

Cited by 3 publications

References 19 publications

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells

Monoclonal antibodies in blood group serology

Enzyme and DTT treatment of adherent RBCs for antibody identification by a solid phase immunoassay system

Contact Info

Product

Resources

About

The Application of Monoclonal Antibodies for the Definition of Genetic Markers of Human Red Cells

Cited by 3 publications

References 19 publications

The A1 (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A1 red cells

The A1 (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A1 red cells

Monoclonal antibodies in blood group serology

Enzyme and DTT treatment of adherent RBCs for antibody identification by a solid phase immunoassay system

Contact Info

Product

Resources

About

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells

The A₁ (B) phenomenon: a monoclonal anti‐B (BS‐85) demonstrates low levels of B determinants on A₁ red cells